Relating plaque morphology to respiratory syncytial virus subgroup, viral load, and disease severity in children

Young-In Kim\textsuperscript{1,2,*}, Ryan Murphy\textsuperscript{1,2,*}, Sirshendu Majumdar\textsuperscript{1,2}, Lisa G. Harrison\textsuperscript{1,2}, Jody Aitken\textsuperscript{2}, and John P. DeVincenzo\textsuperscript{1,2,3}

\textsuperscript{1}Department of Pediatrics, University of Tennessee Health Science Center, Memphis, TN, USA
\textsuperscript{2}Children's Foundation Research Institute at Le Bonheur Children's Hospital, Memphis, TN, USA
\textsuperscript{3}Department of Microbiology, Immunology and Biochemistry, University of Tennessee Health Science Center, Memphis, TN, USA

Abstract

\textbf{Background}—Viral culture plaque morphology in human cell lines are markers for growth capability and cytopathic effect, and have been used to assess viral fitness and select pre-attenuation candidates for live viral vaccines. We classified RSV plaque morphology and analyzed the relationship between plaque morphology as compared to subgroup, viral load and clinical severity of infection in infants and children.

\textbf{Methods}—We obtained respiratory secretions from 149 RSV-infected children. Plaque morphology and viral load was assessed within the first culture passage in HEp-2 cells. Viral load was measured by PCR, as was RSV subgroup. Disease severity was determined by hospitalization, length of stay, intensive care requirement, and respiratory failure.

\textbf{Results}—Plaque morphology varied between individual subjects; however, similar results were observed among viruses collected from upper and lower respiratory tracts of the same subject. Significant differences in plaque morphology were observed between RSV subgroups. No correlations were found among plaque morphology and viral load. Plaque morphology did not correlate with disease severity.

\textbf{Conclusions}—Plaque morphology measures parameters that are viral-specific and independent of the human host. Morphologies vary between patients and are related to RSV subgroup. In HEp-2 cells, RSV plaque morphology appears unrelated to disease severity in RSV-infected children.
Introduction

Disease severity in infants with a primary RSV infection varies dramatically, with most infants not requiring hospitalization. In others, the infection produces much more severe disease, and can result in hospitalization, supplemental oxygen requirement, respiratory failure, and even death. Although host factors, including the presence of pre-existing lung or heart disease, prematurity, and maternal-derived pre-existing humoral neutralizing antibody concentrations, account for some of these differences, they are not sufficient to fully explain the range of disease severity. Host genetic factors also account for some of these severity differences (1, 2), but studies in identical twins have calculated that genetic factors explain only 16% of these differences (3).

Viral-specific factors as causes of significant clinical disease severity differences have been identified in many other viral infections (4-6). Viral load has been clearly identified as a major risk factor in disease severity, but it represents a complex dynamic between host immune responses and intrinsic viral characteristics. RSV subgroup A has been shown to be associated with slightly greater disease severity than RSV subgroup B in several studies (7, 8), but in others, such a difference was not evident (9, 10). Certain regions of the RSV-G (secretory or membrane-bound) protein are pro-inflammatory and mimic the human CXC3 chemokine. One study sequencing the G gene suggested a relationship with RSV disease severity (11).

Intrinsic viral properties are responsible for growth characteristics in vitro, such as plaque morphology. Viruses that form small plaques have traditionally been chosen as pre-attenuation subgroups from which to develop attenuated live viral vaccines. However, for RSV, no clinical rationale exists for this selection practice.

We therefore evaluated the relationship between classifications of plaque morphology as compared to subgroup, viral load and clinical severity of infection in infants and children.

Results

RSV plaque formation begins with a single infectious focus. This infection expands outward to form a visible plaque. HEp-2 cells are non-polarized cells, continuously multiplying throughout the duration of the 5-day plaque assay culture. Within the HEp-2 cell plaque assay system, RSV infection spreads in two ways: 1) directly from cell-to-cell via the fusion of adjacent cells' plasma membranes forming visible syncytia, and 2) through the elaboration of free virus, the diffusion of which is limited within the plaque assay to only the neighboring cells because of the high viscosity of the methylcellulose overlay.

Patient population

Plaque morphology was evaluated on 149 enrolled subjects who were PCR-positive for RSV. The characteristics of these subjects are described in Table 1. The enrolled population was a previously healthy group of children who, given the predictable seasonality of RSV, were likely to be experiencing their first RSV infection. As per the exclusion criteria, they had no known hemodynamically significant congenital heart disease, chronic lung disease,
or known immune deficiency. The duration of symptoms prior to specimen collection for culture and plaque morphology assessment was 4.8 ± 2.4 days (mean ± SD), placing the time of virus collection early in the course of infection and around the time of peak viral load (12, 13)

Diversity of plaque morphology

There was a great amount of diversity in plaque morphology in the primary HEp-2 cell plaque assays (Figure 1). After observing over 100 plates, we developed a system to categorize plaque morphology in the hematoxylin and eosin stained monolayers. If the virus-infected monolayer in the central portion of the plaque remained, it was defined as capped, whereas if the central portion did not remain, it was defined as uncapped. Plaques with well-defined borders were described as sharp, while plaques with undefined, finger-like, or pseudopodic borders were categorized as not sharp. One hundred and forty one samples were culture-positive with sufficient growth to quantify by culture. Of these, 14 samples had a viral quantity which produced plaques too numerous to individually count. The viral loads for these samples were set at the upper level of quantification (6.78 log PFU/ml). Because of the density of these plaques, they also could not be sized accurately. Thus, a different number of patients were evaluated for plaque morphology and viral load comparisons (Table 2). The mean plaque size (diameter) of each patient’s isolate varied substantially (range 265.2-975 μm). The percentage of capped plaques between patients also varied substantially (range 1-100%). Plaques were observed to be either sharp or not sharp, with 70.5% of patient isolates forming plaques with not sharp characteristics (Figure 1, Table 2).

Relationship among patient’s viral plaque characteristics

Certain plaque characteristics were statistically associated with certain RSV subgroups. RSV subgroups were categorized as RSV-A or -B based on N-gene conserved sequences (14). RSV-A plaques were significantly larger (Figure 2a) and less likely to be capped (Figure 2b) compared to those produced by RSV-B. Both viral load by PCR (Figure 2c) and by quantitative culture (infectious virus) (Figure 2d) were greater in patients with RSV-A (Figure 2c and d). Whether or not a patient’s plaques were sharp or not did not vary by RSV subgroup (Figure 2e). The plaque size did not appear to correlate with RSV load, as assessed either by PCR (Figure 3a-c) or by quantitative culture (infectious virus) (Figure 3d-f). As the plaque size increased, the percentage of capped plaques within a patient’s culture significantly decreased (Figure 3g-h). The percentage of capped plaques was not significantly correlated with the patient’s RSV load (Figure 3j-o). The sharpness of each patient’s isolate did not vary by viral load (Figure 4a and 4b) but it was correlated with plaque morphology characteristics (Figure 4c and 4d).

Plaque morphologies and clinical disease

Subjects were classified into different degrees of disease severity. There were no observed associations between plaque morphology and the severity of the patient’s disease (Figures 5 and 6).
**Plaque characteristics from upper and lower respiratory tracts**

Although there was marked diversity of plaque size and plaque morphology among the isolates of different patients, there was a striking similarity of plaque size and morphology within the same patient on different days (data not shown) and within the same patient on the same day but collected from the upper versus the lower respiratory tract (Figure 7). There were seven patients for whom there was access to their lower respiratory tracts at enrollment. For these patients, the plaque characteristics were compared between their upper respiratory tract (nasal wash) and lower respiratory tract (deep tracheal aspirate) samples. The sharpness, percentage of capped plaques and plaque sizes were similar from these two anatomic sites (Figure 7). The morphology of plaques from tracheal aspirates and nasal washes from the same individual at the same evaluation time point were not sharp in both samples for four patients, and sharp in both for two patients. One patient showed different plaque types between upper and lower respiratory tracts. The plaques displayed a sharp in the tracheal sample and a not sharp in the nasal wash sample. We only evaluated five paired nasal wash and tracheal aspirate samples because one nasal wash from one subject and one tracheal aspirate from the other subject produced plaques that were so numerous that they overlapped each other on the plate and did not allow accurate classification.

**Discussion**

Viral growth characteristics in cell culture, including plaque morphology, have been related to pathogenesis and disease severity for several human pathogens. It was shown that small plaque variants are related to virulence, propagation and disease severity in multiple viruses. With herpes simplex virus 1 (HSV1), a small plaque phenotype associated with neuroinvasive disease, was isolated from the central nervous system of a severely affected infant (15, 16). Subsequent passage of this small plaque phenotype virus produced larger plaques that lost their *in vivo* neuroinvasive properties (17). The neuroinvasiveness was suggested to be the result of lower efficiency of viral glycoprotein processing. In West Nile virus, a small plaque phenotype showed less efficiency of replication in *in vitro* culture compared to wild type (18), and it was attenuated in neuroinvasiveness (19). Chemically produced mutants of dengue virus type 4 and tick-borne encephalitis virus display characteristics of small plaque morphology, temperature sensitivity, and attenuated pathogenicity (20, 21). Neuroblastoma cell-adapted yellow fever 17D virus also presents a small plaque phenotype, defective in cell penetration and attenuated growth efficiency (22-24). Plaque size has also been shown to differ among different strains of the influenza A H1N1 subtype. These plaque sizes have been linked *via* mathematical models to fundamental differences in key parameters which characterize the virus replication fitness of these different strains (25).

Viral load drives human RSV disease severity (12, 13, 26, 27). But, viral load is a complex interplay among viral-specific factors and the dynamic host factors of innate immunity and cognate immune responses. Studying the role of viral-specific factors is challenging for RSV because it cannot be reliably cultured after a single freeze-thaw cycle. Also, because RSV is an RNA virus, its mutation rate is rapid even within a single patient (28). Plaque size from clinical isolates was shown in other viruses to change significantly even over the first
several passages in tissue culture (17, 29). Therefore, when studying viral-specific factors, low-passage clinical isolates need to be utilized. Plaque morphology differences within a single uniform cell line are products of viral-specific factors. In the present study, the plaque assays from the evaluated patients were performed on fresh respiratory samples under identical conditions (12, 14). Since plaques were evaluated in dilute respiratory secretions, (generally 100 to 1,000-fold dilutions) and not within an undiluted sample, any putative host effect existing within the secretions was greatly diluted and likely not to affect plaque morphology. Thus, the morphology of the plaque at a time point after inoculation represents an intrinsic viral-specific factor related to growth kinetics within that particular uniform cell line (12, 14). Here, we evaluate viral-specific characteristics within the first culture passage of multiple RSV clinical isolates.

We chose to study these viral-specific factors as early as possible in the course of disease in a population of infants who are likely to be experiencing their first RSV infection and who are immunologically naïve to the virus. Furthermore, we selected a population that was as homogeneous as possible, so we could detect viral-specific differences unencumbered by differences in disease severity that might be determined more by the underlying co-morbidities of the host.

We show for the first time that plaque size and morphology differ dramatically between infected individuals, but that within the same individual, these viral-specific factors appear conserved (Figure 7). These differences appear to be related to viral group, but even within RSV-A and RSV-B isolates, major differences in size and morphology were clearly observed (Figures 2a, 2b, 2e and 3).

RSV-A has been shown in multiple studies to cause more severe disease than does RSV-B. A recent multicenter large survey of children confirms this disease severity association (30). We have previously shown that viral load is higher in infants infected with RSV-A compared to RSV-B ((14), Figure 2c and 2d). Our results suggest that intrinsic viral growth characteristics, not just host response factors, play a role in the viral load differences observed in infected patients. RSV-A produced significantly larger plaques than RSV-B. In addition to plaque size differences, the RSV-A plaques shed their caps more frequently than RSV-B plaques (Figure 2b). The fact that the infected cells within the monolayer were affected differently in infections with RSV-A compared to RSV-B suggests that there may be differences in the cytopathologic potential of these two RSV subgroups in addition to intrinsic viral replication parameters.

Whole viral genome sequencing has yet to be performed in large-scale clinical studies of RSV infection. However, it appears that intrinsic viral growth kinetic properties and/or cytopathogenic properties may in part drive human RSV disease severity. Plaque size has been used to pre-select certain viral subgroups as low virulence candidates for further attenuation. The lack of correlation between plaque size and disease severity suggests that this assumption could be incorrect.

HEp-2 cells are different from respiratory epithelial cells, which are the primary infected target cells in human RSV infection. As opposed to the epithelial cells of the human
respiratory tract, HEp-2 cells are not polarized, and do not reach static growth rates in tissue culture. In natural human RSV infection, the virus is released preferentially from the apical surface of polarized respiratory epithelial cells. Because of these cellular differences, clinical RSV strains are likely to show different first-passage growth characteristics in HEp-2 cells compared to the human respiratory epithelial cells in which they were adapted for rapid growth. This limitation may explain why we did not observe a correlation between plaque size or morphology and disease severity (Figure 5 and 6).

The temperature of the human nose is significantly lower (32°C) than the core body temperature (37°C) in the lower respiratory tract (31). This temperature difference and the relative viral replicative fitness at these different temperatures has been leveraged in previous experimental live RSV vaccines (32-35) and in the licensed live attenuated influenza vaccine (36). We compared the plaque morphology of the RSV isolated from selected patients' upper respiratory tract with that collected at the same time from their lower respiratory tract (Figure 7). After culturing them at the same temperature and in identical conditions, the plaque characteristics these two anatomic sites were remarkably similar.

In conclusion, viral-specific factors related to growth characteristics are similar within individual RSV-infected patients, but are remarkably different among patients. These RSV-specific growth characteristics may point to viral factors, which may explain differences in disease severity. Further studies of whole viral genome sequencing from clinical specimens and relating these sequences to observed viral properties and clinical disease severity should be encouraged.

**Methods**

**Study subjects**

Study subjects were less than two years of age (n = 149) and had acute onset of respiratory infection that tested positive for RSV by PCR. Respiratory secretions collected on the first day of enrollment were utilized for plaque descriptions. Subjects were born at term and were previously healthy. Patients with chronic lung disease, hemodynamically significant congenital heart disease, immunodeficiency, RSV prophylactic treatment or any steroid use were excluded. This study was conducted with the approval of the University of Tennessee Institutional Review Board, included appropriate informed consent, and complied with all relevant guidelines and institutional policies. Nasal washes were performed as previously described (14). Seven of these study subjects had an endotracheal tube in place, therefore providing access to the lower respiratory tract. In these subjects, both a nasal wash and tracheal aspirates were collected at the same times on the first day of enrollment, and on subsequent days. All secretions were collected directly into 4°C sucrose-containing RSV transport media and used for plaque assays within three hours. Other individual aliquots of each respiratory secretion sample were quickly frozen on dry ice and maintained at -80°C until thawed for use in quantitative real-time reverse transcription polymerase chain reaction (qRTrtPCR) assays (37). Multiplexed PCR detection of respiratory viruses other than RSV was not performed. However, viruses known to be associated with RSV co-detections (rhinoviruses, adenoviruses, hMPV, and coronaviruses) do not grow or do not produce visible plaques in our HEp-2 cell culture system.
**RSV culture**

Plaque assays were performed as previously described (14) using the human RSV-A, Long strain ATCC VR-26 as a quantitative standard. Briefly, 4 ten-fold dilutions (ranging from undiluted to 1:1,000) of fresh respiratory secretions were prepared and placed in triplicate in twelve-well culture plates containing 80% confluent HEp-2 cells. Secretions were incubated for 1 hour and then overlayed with 1 ml of pre-warmed 0.75% methylcellulose-containing growth media without rinsing the initial inoculum. Plates were incubated for five days at 37°C (5% CO2) and then formalin fixed and stained with hematoxylin and eosin for plaque counting and morphology observation. The quantitative culture's minimum and maximum quantifiable RSV concentration was 0.48-6.78 log PFU/ml.

**Plaque morphology**

Plaque morphology was determined by investigators who were masked with respect to the patient's clinical outcome, RSV subgroup, viral load and anatomic sites of sample acquisition. **Plaque size:** For each plate, five individual plaques representative of the viral population (not touching edges of the well) were measured at 40X magnification. The longest vertical and horizontal axis for each plaque was averaged and converted to micrometers using the standard ocular division calculation for the microscope and magnification. **Sharpness:** Some inter-plaque variability was present within a single patient's viral isolate. Therefore, for each patient's entire plaque population, the majority of viral plaques were described as either being sharp or not sharp. Plaques with well-defined borders were described as sharp, while plaques with undefined, finger-like borders were categorized as not sharp. Standard representative plates containing sharp plaques and not sharp plaques were reviewed by the investigators after every ten study plates were viewed (Figure 1). **Capping:** If the virus-infected HEp-2 cell monolayer of the central portion of the plaque remained, this was called capped, whereas if the central portion did not remain, it was categorized as uncapped (Figure 1). For each patient sample, 50-100 plaques were counted per well at 40X magnification, and the percentage of completely formed caps was calculated.

**Disease severity parameters used**

Because of their clinical relevance, hospitalization, duration of hospital stay, requirement for Intensive Care Unit (ICU) management and respiratory failure (requiring intubation) were used as disease severity indicators.

**Statistical analysis**

Statistical analysis was performed using standard techniques. D'Agostino and Pearson omnibus normality tests were performed to determine the nature of the data distribution. For normally distributed data, the t-test was used. The non-parametric Mann Whitney U test was used for data that were not normally distributed. All tests were two-tailed with the level of significance set at 0.05. For consistency of visualization, lines on the scattergrams represent means and standard error margins regardless of the statistical test used for comparison. Continuous variables were analyzed using linear regression with 95% confidence intervals of their slopes represented by dashed lines. Statistical significance was achieved if the 95%
confidence intervals of the slopes of the regression lines excluded a slope of zero. No data manipulation was performed on quantitative culture-determined viral load data points, which exceeded the upper limit of quantification. Fisher's exact test and the Chi-square test were used for the contingency graphs. Statistical analyses and construction of figures were performed with GraphPad Prism Software v5.0 (La Jolla, CA).

Acknowledgments

The authors thank April Sullivan for her technical help in the laboratory and Andrea Patters for her assistance with the preparation of the manuscript. We thank the parents and caregivers of the participating infants and children, without whose altruism the advancement towards therapy and prevention of RSV would be impossible.

Financial support: This research was funded by the National Institutes of Health (NIH), 9000 Rockville Pike, Bethesda, MD, US, grants R07322303 and RR16187 awarded to Dr. DeVincenzo.

References

1. El Saleeby CM, Li R, Somes GW, et al. Surfactant protein A2 polymorphisms and disease severity in a respiratory syncytial virus-infected population. J Pediatr. 2010; 156:409–14. [PubMed: 19914637]
2. Miyairi I, DeVincenzo JP. Human genetic factors and respiratory syncytial virus disease severity. Clin Microbiol Rev. 2008; 21:686–703. [PubMed: 18854487]
3. Thomsen SF, Stensballe LG, Skytte A, et al. Increased concordance of severe respiratory syncytial virus infection in identical twins. Pediatrics. 2008; 121:493–6. [PubMed: 18310197]
4. Fraser C, Lythgoe K, Leventhal GE, et al. Virulence and pathogenesis of HIV-1 infection: an evolutionary perspective. Science. 2014; 343:1243727. [PubMed: 24653038]
5. Hakami A, Ali A, Hakami A. Effects of hepatitis B virus mutations on its replication and liver disease severity. Open Virol J. 2013; 7:12–8. [PubMed: 23400390]
6. Goka EA, Vallely PJ, Mutton KJ, Klapper PE. Mutations associated with severity of the pandemic influenza A(H1N1)pdm09 in humans: a systematic review and meta-analysis of epidemiological evidence. Arch Virol. 2014
7. Heikkinen T, Waris M, Ruuskanen O, Putto-Laurila A, Mertsola J. Incidence of acute otitis media associated with group A and B respiratory syncytial virus infections. Acta Paediatr. 1995; 84:419–23. [PubMed: 7795353]
8. Walsh EE, McConnochie KM, Long CE, Hall CB. Severity of respiratory syncytial virus infection is related to virus strain. J Infect Dis. 1997; 175:814–20. [PubMed: 9086135]
9. Kneyber MC, Brandenburg AH, Rothbarth PH, et al. Relationship between clinical severity of respiratory syncytial virus infection and subtype. Arch Dis Child. 1996; 75:137–40. [PubMed: 8869195]
10. McIntosh ED, De Silva LM, Oates RK. Clinical severity of respiratory syncytial virus group A and B infection in Sydney, Australia. Pediatr Infect Dis J. 1993; 12:815–9. [PubMed: 8284117]
11. Martinello RA, Chen MD, Weibel C, Kahn JS. Correlation between respiratory syncytial virus genotype and severity of illness. J Infect Dis. 2002; 186:839–42. [PubMed: 12198620]
12. El Saleeby CM, Bush AJ, Harrison LM, Aitken JA, Devincenzo JP. Respiratory syncytial virus load, viral dynamics, and disease severity in previously healthy naturally infected children. J Infect Dis. 2011; 204:996–1002. [PubMed: 21881113]
13. DeVincenzo JP, El Saleeby CM, Bush AJ. Respiratory syncytial virus load predicts disease severity in previously healthy infants. J Infect Dis. 2005; 191:1861–8. [PubMed: 15871119]
14. DeVincenzo JP. Natural infection of infants with respiratory syncytial virus subgroups A and B: a study of frequency, disease severity, and viral load. Pediatr Res. 2004; 56:914–7. [PubMed: 15470202]
15. Dick JW, Rosenthal KS. A block in glycoprotein processing correlates with small plaque morphology and virion targeting to cell-cell junctions for an oral and an anal strain of herpes simplex virus type-1. Arch Virol. 1995; 140:2163–81. [PubMed: 8572939]

16. Goel N, Mao H, Rong Q, et al. The ability of an HSV strain to initiate zosteriform spread correlates with its neuroinvasive disease potential. Arch Virol. 2002; 147:763–73. [PubMed: 12038686]

17. Mao H, Rosenthal KS. Strain-dependent structural variants of herpes simplex virus type 1 ICP34.5 determine viral plaque size, efficiency of glycoprotein processing, and viral release and neuroinvasive disease potential. J Virol. 2003; 77:3409–17. [PubMed: 12610116]

18. Jia Y, Moudy RM, Dupuis AP 2nd, et al. Characterization of a small plaque variant of West Nile virus isolated in New York in 2000. Virology. 2007; 367:339–47. [PubMed: 17617432]

19. Davis CT, Beasley DW, Guzman H, et al. Emergence of attenuated West Nile virus variants in Texas, 2003. Virology. 2004; 330:342–50. [PubMed: 15527859]

20. Blaney JE Jr, Johnson DH, Manipon GG, et al. Genetic basis of attenuation of dengue virus type 4 small plaque mutants with restricted replication in suckling mice and in SCID mice transplanted with human liver cells. Virology. 2002; 300:125–39. [PubMed: 12202213]

21. Rumyantsev AA, Murphy BR, Pletnev AG. A tick-borne Langat virus mutant that is temperature sensitive and host range restricted in neuroblastoma cells and lacks neuroinvasiveness for immunodeficient mice. J Virol. 2006; 80:1427–39. [PubMed: 16415020]

22. Nickells M, Chambers TJ. Neuroadapted yellow fever virus 17D: determinants in the envelope protein govern neuroinvasiveness for SCID mice. J Virol. 2003; 77:12232–42. [PubMed: 14581560]

23. Vlaycheva LA, Chambers TJ. Neuroblastoma cell-adapted yellow fever 17D virus: characterization of a viral variant associated with persistent infection and decreased virus spread. J Virol. 2002; 76:6172–84. [PubMed: 12021351]

24. Vlaycheva L, Nickells M, Droll DA, Chambers TJ. Neuroblastoma cell-adapted yellow fever virus: mutagenesis of the E protein locus involved in persistent infection and its effects on virus penetration and spread. J Gen Virol. 2005; 86:413–21. [PubMed: 15659761]

25. Holder BP, Simon P, Liao LE, et al. Assessing the in vitro fitness of an oseltamivir-resistant seasonal A/H1N1 influenza strain using a mathematical model. PLoS One. 2011; 6:e14767. [PubMed: 21455300]

26. DeVincenzo JP, Wilkinson T, Vaishnaw A, et al. Viral load drives disease in humans experimentally infected with respiratory syncytial virus. Am J Respir Crit Care Med. 2010; 182:1305–14. [PubMed: 20622030]

27. Buckingham SC, Bush AJ, Devincenzo JP. Nasal quantity of respiratory syncytial virus correlates with disease severity in hospitalized infants. Pediatr Infect Dis J. 2000; 19:113–7. [PubMed: 10693996]

28. Grad YH, Newman R, Zody M, et al. Within-host whole-genome deep sequencing and diversity analysis of human respiratory syncytial virus infection reveals dynamics of genomic diversity in the absence and presence of immune pressure. J Virol. 2014; 88:7286–93. [PubMed: 24741088]

29. Bower JR, Mao H, Durishin C, et al. Intrastain variants of herpes simplex virus type 1 isolated from a neonate with fatal disseminated infection differ in the ICP34.5 gene, glycoprotein processing, and neuroinvasiveness. J Virol. 1999; 73:3843–53. [PubMed: 10196279]

30. Jafri HS, Wu X, Makari D, Henrickson KJ. Distribution of respiratory syncytial virus subtypes A and B among infants presenting to the emergency department with lower respiratory tract infection or apnea. Pediatr Infect Dis J. 2013; 32:335–40. [PubMed: 23337904]

31. Scull MA, Gillim-Ross L, Santos C, et al. Avian Influenza virus glycoproteins restrict virus replication and spread through human airway epithelium at temperatures of the proximal airways. PLoS Pathog. 2009; 5:e1000424. [PubMed: 19436701]

32. Crowe JE Jr, Collins PL, London WT, Chanock RM, Murphy BR. A comparison in chimpanzees of the immunogenicity and efficacy of live attenuated respiratory syncytial virus (RSV) temperature-sensitive mutant vaccines and vaccinia virus recombinants that express the surface glycoproteins of RSV. Vaccine. 1993; 11:1395–404. [PubMed: 8310760]

33. Firestone CY, Whitehead SS, Collins PL, Murphy BR, Crowe JE Jr. Nucleotide sequence analysis of the respiratory syncytial virus subgroup A cold-passaged (cp) temperature sensitive (ts)
cpts-248/404 live attenuated virus vaccine candidate. Virology. 1996; 225:419–22. [PubMed: 8918930]

34. Juhasz K, Whitehead SS, Bui PT, et al. The temperature-sensitive (ts) phenotype of a cold-passaged (cp) live attenuated respiratory syncytial virus vaccine candidate, designated cpts530, results from a single amino acid substitution in the L protein. J Virol. 1997; 71:5814–9. [PubMed: 9223470]

35. Karron RA, Wright PF, Crowe JE Jr, et al. Evaluation of two live, cold-passaged, temperature-sensitive respiratory syncytial virus vaccines in chimpanzees and in human adults, infants, and children. J Infect Dis. 1997; 176:1428–36. [PubMed: 9395351]

36. Zhou B, Li Y, Speer SD, et al. Engineering temperature sensitive live attenuated influenza vaccines from emerging viruses. Vaccine. 2012; 30:3691–702. [PubMed: 22449422]

37. Perkins SM, Webb DL, Torrance SA, et al. Comparison of a real-time reverse transcriptase PCR assay and a culture technique for quantitative assessment of viral load in children naturally infected with respiratory syncytial virus. J Clin Microbiol. 2005; 43:2356–62. [PubMed: 15872266]
Figure 1. Plaque morphology
HEp-2 cells were exposed to nasal washes for one hour, overlaid with methylcellulose and incubated for five days, then fixed and stained with hematoxylin and eosin. Plaques from 4 different subjects are shown. (a) Capped sharp plaque, (b) Uncapped sharp plaque, (c) Uncapped not sharp plaque and (d) Capped not sharp plaque. All panels were photographed at 40X total magnification.
Figure 2. RSV subgroup, plaque morphology and viral load
RSV subgroups A and B versus (a) plaque size (RSV-A (n=85), RSV-B (n=35)), (b) % capped plaques (RSV-A (n=85), RSV-B (n=35)), (c) viral load by PCR (RSV-A (n=104), RSV-B (n=45)), (d) viral load by quantitative culture (infectious) (RSV-A (n=104), RSV-B (n=45)), and (e) Plaque sharpness versus RSV subgroups (RSV-A: not sharp (n=75), sharp (n=22), RSV-B: not sharp (n=30), sharp (n=7)). Open bars represent not sharp and black bars represent sharp plaques. Mann Whitney U test was used in panels a-d. All P values reflect significant observed differences among RSV subgroups (*P<0.05; †P<0.0005).
Figure 3. Plaque morphology and viral load
Plaque size versus total viral load by PCR in RSV subgroups (a) A and B (n=120), (b) subgroup A (n=85) and (c) subgroup B (n=35). Plaque size versus viral load by quantitative culture (infectious) in RSV subgroups (d) A and B (n=120), (e) subgroup A (n=85) and (f) subgroup B (n=35). Plaque size versus % Capped in RSV subgroups (g) A and B (n=120, †P<0.0005), (h) subgroup A (n=85, †P<0.0005) and (i) subgroup B (n=35). % Capped versus total viral load by PCR RSV subgroups (j) A and B (n=120), (k) subgroup A (n=85) and (l) subgroup B (n=35). % Capped versus viral load by quantitative culture (infectious) RSV subgroups (m) A and B (n=120), (n) subgroup A (n=85) and (o) subgroup B (n=35).
Figure 4. Plaque morphology and viral load in plaque sharpness
Plaque sharpness versus (a) total viral load by PCR (not sharp (n=105), sharp (n=29)) and (b) viral load by quantitative culture (infectious) (not sharp (n=105), sharp (n = 29)), (c) plaque size (not sharp (n=91), sharp (n=29)) and (d) percentage of capped plaques (not sharp (n=91), sharp (n=29)). Mann Whitney U test was used in panels a, b and d and t-test was used in panel c. All P values reflect significant observed differences between sharp and not sharp plaques (*P<0.05, **P<0.005).
Figure 5. Plaque size and disease severity
Plaque size versus (a) hospital admission (admitted (n=104), not admitted (n=16)), (b) duration of hospitalization (n=120), (c) requirement for intensive care (ICU (n=22), non-ICU (n=98)) and (d) respiratory failure (intubated (n=16), not intubated (n=104)). Data contain both RSV-A- and RSV-B-infected patients whose duration of hospitalization, respiratory failure, and ICU admission were evaluated retrospectively upon discharge. The t-test was used in panels a, c and d.
Figure 6. Plaque morphology and disease severity

Percentage of capped plaques versus (a) hospital admission (admitted (n=104), not admitted (n=16)), (b) duration of hospitalization (n=120), (c) requirement for intensive care (ICU (n=22), non-ICU (n=98)) and (d) respiratory failure (intubated (n=16), not intubated (n=104)). (e) Plaque sharpness versus duration of hospitalization (not sharp (n=105), sharp (n=29)). (f) Plaque sharpness versus hospital admission (admitted: not sharp (n=85), sharp (n=27), not admitted: not sharp (n=20), sharp (n=2)), requirement for intensive care (ICU: not sharp (n=15), sharp (n=9), non-ICU: not sharp (n=90), sharp (n=20)) or respiratory failure (intubated: not sharp (n=12), sharp (n=6), not intubated: not sharp (n=93), sharp (n=23)). Open bars represent not sharp and black bars represent sharp plaques. The analyses were not statistically significant (P >0.05). Data contain both RSV-A- and RSV-B-infected patients whose duration of hospitalization, respiratory failure, and ICU admission were evaluated retrospectively upon discharge. The Mann Whitney U test was used in panels a and c-e.
Figure 7. Upper and lower respiratory plaque morphology within individuals

For patients with both nasal and tracheal aspirates acquired on the day of enrollment ($n=7$), *in vitro* viral plaque populations grew with similar morphologies, (a) plaque size (b) percent capped, and produced similar ratios of PCR-measured viral load and quantitative culture (infectious) viral load (c) PFUe/PFU even though secretions were retrieved from different anatomical locations. Each patient represents one data point. Plaque morphologies were adjudicated by investigators who were masked with respect to source of specimen, clinical disease severity, RSV subgroup or any patient characteristics.
| Characteristics | No. of subjects (n=149) | Mean±SD |
|-----------------|-------------------------|---------|
| Gender          |                         |         |
| Female          | 80 (53.7%)              |         |
| Male            | 69 (46.3%)              |         |
| Race            |                         |         |
| Caucasian       | 56 (37.6%)              |         |
| African American| 93 (62.4%)              |         |
| Birth defects   |                         |         |
| Congenital anomalies | 1 (0.7%) |         |
| No anomalies    | 148 (99.3%)             |         |
| Hospitalized    |                         |         |
| Admitted        | 125 (83.9%)             |         |
| Not admitted    | 24 (16.1%)              |         |
| ICU admittance  |                         |         |
| ICU             | 26 (17.4%)              |         |
| Non ICU         | 123 (82.6%)             |         |
| Respiratory failure |                |         |
| Intubated       | 20 (13.4%)              |         |
| Not intubated   | 129 (86.6%)             |         |
| Breastfeeding   |                         |         |
| Breastfed       | 71 (47.7%)              |         |
| Not breastfed   | 78 (52.3%)              |         |
| Smoking in household |               |         |
| Tobacco exposure| 44 (29.5%)              |         |
| No tobacco exposure | 105 (70.5%) |         |
| Age at time of admission (days) | 115.0 ±109.2 |         |
| Estimated gestational age (weeks) | 38.0 ± 3.0 |         |

*ICU, intensive care unit*
**Table 2**

Viral characteristics

| Characteristics | No. of subjects (n = 149) | Mean ± SD |
|-----------------|----------------------------|-----------|
| **Subgroup**    |                            |           |
| RSV A           | 104 (69.8%)                |           |
| RSV B           | 45 (30.2%)                 |           |
| **Plaque invasiveness** |                    |           |
| Not sharp       | 105 (70.5%)                |           |
| Sharp           | 29 (19.5%)                 |           |
| Unclassified    | 15 (10.1%)                 |           |
| **Plaque capping** |                        |           |
| Countable       | 120 (80.5%)                | 52.2 ± 31.1% |
| Uncountable     | 29 (19.5%)                 |           |
| **Plaque size** |                            |           |
| Countable       | 120 (80.5%)                | 564.5 ± 145.1 μm |
| Uncountable     | 29 (19.5%)                 |           |

RSV subgroup analysis was performed by PCR. Plaque morphology, including invasiveness, capping and size analysis was assessed by culture. The yield of PCR data was 100%, but that of culture data was varied.

*a* Fifteen subjects' plaque invasiveness was uncountable because of no growth (NG, n = 8) or too few to count (TFTC, n = 7).

*b* Twenty-nine subjects' plaque capping was uncountable because of NG (n = 8) or TFTC (n = 7) or too numerous to count (TNTC, n = 14).

*c* Twenty-nine subjects' plaque size was uncountable because of NG (n = 8), TFTC (n = 7) or TNTC (n = 14).

*d* The data was averaged per plaque for one patient and then averaged per patient.